📰 Dose Ranging Study News
Dose Ranging Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dose Ranging Study. Real-time updates on events, politics, business and more.
March 9, 2024
/PRNewswire/ -- Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating...
March 9, 2024
Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only...
January 4, 2024
Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). In November, Silo Pharma announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15. The study aims to identify the maximum tolerated intranasal dose ...
September 21, 2023
/PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients...
July 4, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from its Phase 2b FRONTIER 1 clinical trial...
March 6, 2023
Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707)
June 3, 2022
Data presentations provide key updates on the portfolio, including Botulinum Toxin, Belotero, Radiesse and Ultherapy Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics
March 31, 2022
Data presentations provide key updates on the portfolio, including Botulinum Toxin, Belotero, Radiesse and Ultherapy Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics
October 1, 2021
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...
October 1, 2021
/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...